1. Home
  2. UHT vs ALLO Comparison

UHT vs ALLO Comparison

Compare UHT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

UHT

Universal Health Realty Income Trust

HOLD

Current Price

$40.03

Market Cap

596.5M

Sector

Real Estate

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.32

Market Cap

539.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UHT
ALLO
Founded
1986
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
596.5M
539.4M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
UHT
ALLO
Price
$40.03
$2.32
Analyst Decision
Hold
Strong Buy
Analyst Count
1
15
Target Price
$43.00
$8.35
AVG Volume (30 Days)
43.3K
14.6M
Earning Date
04-27-2026
05-07-2026
Dividend Yield
7.33%
N/A
EPS Growth
N/A
34.09
EPS
0.36
N/A
Revenue
$99,190,000.00
N/A
Revenue This Year
$2.12
N/A
Revenue Next Year
$2.94
$142,416.42
P/E Ratio
$111.89
N/A
Revenue Growth
0.18
N/A
52 Week Low
$35.26
$0.86
52 Week High
$44.70
$4.46

Technical Indicators

Market Signals
Indicator
UHT
ALLO
Relative Strength Index (RSI) 38.29 50.39
Support Level $39.47 $2.12
Resistance Level $41.13 $2.76
Average True Range (ATR) 0.82 0.12
MACD -0.05 0.01
Stochastic Oscillator 16.45 72.73

Price Performance

Historical Comparison
UHT
ALLO

About UHT Universal Health Realty Income Trust

Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: